207940 — Samsung Biologics Co Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩55tn
- KR₩55tn
- KR₩4tn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 655,141 | 828,897 | 1,347,450 | 3,171,705 | 2,022,450 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 207,930 | 246,197 | 430,242 | 820,156 | 742,712 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,356,262 | 1,751,347 | 2,823,175 | 6,457,657 | 5,521,988 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,718,911 | 1,760,728 | 2,227,687 | 3,871,452 | 4,342,424 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 5,911,627 | 6,424,201 | 7,970,011 | 16,582,050 | 16,046,197 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 690,505 | 589,301 | 1,107,295 | 4,181,542 | 4,157,861 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 1,557,173 | 1,825,418 | 2,978,909 | 7,597,576 | 6,215,705 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 4,354,454 | 4,598,783 | 4,991,102 | 8,984,474 | 9,830,492 |
Total Liabilities & Shareholders' Equity | 5,911,627 | 6,424,201 | 7,970,011 | 16,582,050 | 16,046,197 |
Total Common Shares Outstanding |